Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $53.49, for a total transaction of $1,007,323.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, August 28th, Clay B. Siegall sold 25,506 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total transaction of $1,221,482.34.
  • On Monday, August 7th, Clay B. Siegall sold 10,413 shares of Seattle Genetics stock. The shares were sold at an average price of $48.91, for a total transaction of $509,299.83.
  • On Wednesday, July 5th, Clay B. Siegall sold 10,423 shares of Seattle Genetics stock. The shares were sold at an average price of $51.98, for a total transaction of $541,787.54.

Seattle Genetics, Inc. (NASDAQ SGEN) traded down 0.91% during mid-day trading on Tuesday, reaching $53.15. The company had a trading volume of 789,458 shares. The firm’s 50-day moving average is $49.74 and its 200-day moving average is $59.41. Seattle Genetics, Inc. has a one year low of $45.31 and a one year high of $75.36. The firm’s market capitalization is $7.60 billion.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm had revenue of $108.20 million for the quarter, compared to analyst estimates of $105.92 million. During the same period in the previous year, the firm earned ($0.23) earnings per share. The company’s revenue was up 13.4% compared to the same quarter last year. On average, equities research analysts anticipate that Seattle Genetics, Inc. will post ($1.69) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Clay B. Siegall Sells 18,832 Shares of Seattle Genetics, Inc. (SGEN) Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/12/clay-b-siegall-sells-18832-shares-of-seattle-genetics-inc-sgen-stock.html.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Seattle Genetics by 2.3% in the second quarter. Vanguard Group Inc. now owns 7,530,515 shares of the biotechnology company’s stock valued at $389,628,000 after buying an additional 167,828 shares during the period. BlackRock Inc. lifted its stake in Seattle Genetics by 2.6% in the second quarter. BlackRock Inc. now owns 7,453,483 shares of the biotechnology company’s stock valued at $385,644,000 after buying an additional 185,823 shares during the period. State Street Corp lifted its stake in Seattle Genetics by 10.9% in the first quarter. State Street Corp now owns 2,845,120 shares of the biotechnology company’s stock valued at $178,847,000 after buying an additional 279,079 shares during the period. Capital International Investors lifted its stake in Seattle Genetics by 34.3% in the second quarter. Capital International Investors now owns 2,724,589 shares of the biotechnology company’s stock valued at $140,970,000 after buying an additional 695,986 shares during the period. Finally, Matrix Capital Management Company LP lifted its stake in Seattle Genetics by 18.8% in the second quarter. Matrix Capital Management Company LP now owns 2,118,000 shares of the biotechnology company’s stock valued at $109,585,000 after buying an additional 335,000 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have issued reports on SGEN shares. Cann restated a “hold” rating on shares of Seattle Genetics in a research report on Tuesday, August 29th. J P Morgan Chase & Co restated a “hold” rating and set a $58.00 target price on shares of Seattle Genetics in a research report on Tuesday, June 13th. Cantor Fitzgerald restated a “hold” rating and set a $43.00 target price on shares of Seattle Genetics in a research report on Monday, June 26th. Piper Jaffray Companies restated a “neutral” rating and set a $48.00 target price on shares of Seattle Genetics in a research report on Tuesday, June 27th. Finally, Cowen and Company set a $61.00 target price on shares of Seattle Genetics and gave the company a “hold” rating in a research report on Tuesday, June 6th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $62.29.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.